Iniciar sesión
Registrarse
Restablecer contraseña
Publicar y Distribuir
Soluciones de Publicación
Soluciones de Distribución
Temas
Arquitectura y diseño
Artes
Ciencias Sociales
Ciencias de la Información y Bibliotecas, Estudios del Libro
Ciencias de la vida
Ciencias de los materiales
Deporte y tiempo libre
Estudios clásicos y del Cercano Oriente antiguo
Estudios culturales
Estudios judíos
Farmacia
Filosofía
Física
Geociencias
Historia
Informática
Ingeniería
Interés general
Ley
Lingüística y semiótica
Literatura
Matemáticas
Medicina
Música
Negocios y Economía
Química
Química industrial
Teología y religión
Publicaciones
Revistas
Libros
Actas
Editoriales
Blog
Contacto
Buscar
EUR
USD
GBP
Español
English
Deutsch
Polski
Español
Français
Italiano
Carrito
Home
Revistas
Asian Biomedicine
Volumen 16 (2022): Edición 2 (April 2022)
Acceso abierto
Atorvastatin reduces alloxan-induced impairment of aversive stimulus memory in mice
Osman Kukula
Osman Kukula
y
Caner Günaydın
Caner Günaydın
| 29 abr 2022
Asian Biomedicine
Volumen 16 (2022): Edición 2 (April 2022)
Acerca de este artículo
Artículo anterior
Artículo siguiente
Resumen
Artículo
Figuras y tablas
Referencias
Autores
Artículos en este número
Vista previa
PDF
Cite
Compartir
Article Category:
Original article
Publicado en línea:
29 abr 2022
Páginas:
71 - 78
DOI:
https://doi.org/10.2478/abm-2022-0009
Palabras clave
alloxan
,
atorvastatin
,
avoidance learning
,
diabetes mellitus
,
experimental
,
memory
© 2022 Osman Kukula et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Figure 1
(A) Mouse weight throughout the experiment analyzed with a general linearized model. #P < 0.05, ###P < 0.001 alloxan-induced diabetes vs. vehicle control. ***P < 0.001 liraglutide + alloxan-induced diabetes vs. alloxan-induced diabetes. (B) Blood glucose levels after oral glucose administration for each experimental group in the OGTT. (C) Locomotor activity for each experimental group. Statistical analyses were conducted using a one-way ANOVA with a Tukey post hoc test. Data are represented as mean ± standard deviation. ANOVA, analysis of variance; Ator, atorvastatin; Control, saline vehicle treatment alone as a negative control; DM, alloxan-induced model of diabetes mellitus; OGTT, oral glucose tolerance test.
Figure 2
Effect of each drug treatment on (A) initial latency and (B) retention period latency in the passive avoidance test. There were no significant differences in initial latency between experimental groups. Alloxan-induced diabetes significantly decreased retention period latency. #P < 0.05 vs. vehicle control. Atorvastatin significantly attenuated the alloxan-induced diabetes decrease in retention period latency. *P < 0.05 vs. alloxan-induced diabetes; +P < 0.05 vs. alloxan-induced diabetes + liraglutide. Liraglutide also significantly attenuated the alloxan-induced diabetes decrease in retention period latency even more than atorvastatin. ***P < 0.001. Symbols represent each data point and the bar indicates mean ± standard deviation. Statistical analyses were performed using a Kruskal–Wallis test. Ator, atorvastatin; Control, saline vehicle treatment alone as a negative control; DM, alloxan-induced model of diabetes mellitus.
Figure 3
The amount of time spent in the dark compartment by mice in each experimental group. Alloxan-induced diabetes significantly increased the time spent in the dark compartment. #P < 0.05 vs. saline vehicle control. Atorvastatin attenuated this increase in mice with alloxan-induced diabetes. *P < 0.05 vs. alloxan-induced diabetes; +P < 0.05 vs. alloxan-induced diabetes + liraglutide. Liraglutide significantly attenuated the time mice with alloxan-induced diabetes spent in the dark compartment. ***P < 0.001 vs. alloxan-induced diabetes. Symbols represent each data point and the bars indicate mean ± standard deviation. Statistical analyses were performed using a one-way ANOVA with a Tukey post hoc test. ANOVA, analysis of variance; Ator, atorvastatin; Control, saline vehicle treatment alone as a negative control; DM, alloxan-induced model of diabetes mellitus.
Vista previa